Fluoroquinolone Adverse Effects
Infectious Disease
Illness script · Infectious Disease
Fluoroquinolone Adverse Effects
Broad-spectrum antibiotics (ciprofloxacin, levofloxacin, moxifloxacin) with a distinctive toxicity profile spanning tendons, CNS, cardiac conduction, and glucose regulation.
This illness script for Fluoroquinolone Adverse Effects covers predisposing factors, classic presentation, mechanism, workup, management, and the clinical pivots that separate it from look-alikes—written for USMLE Step 1 and clerkship reasoning.
01
Predisposing factors
- Age >60 yr: highest risk for Achilles tendon rupture
- Concurrent corticosteroid use dramatically amplifies tendinopathy risk
- Renal impairment: reduced drug clearance increases systemic exposure
- Seizure disorder or CNS pathology: lowers seizure threshold further
- Hypokalemia/hypomagnesemia or baseline QTc >450 ms: additive arrhythmia risk
- Diabetes on sulfonylureas: severe dysglycemia, especially with gatifloxacin
02
Presentation
- Achilles tendinitis or spontaneous rupture (during course or up to weeks after)
- QTc prolongation → palpitations, syncope, torsades de pointes
- Seizures, confusion, dizziness (especially elderly or CNS-susceptible patients)
- Phototoxicity: severe sunburn-like eruption with minimal UV exposure
- Peripheral neuropathy: burning, tingling, weakness — may be irreversible
- Dysglycemia: hypoglycemia (with sulfonylureas) or hyperglycemia
03
Pathophysiology
- Inhibit bacterial DNA gyrase (topoisomerase II) & topoisomerase IV → bactericidal
- Tendon toxicity: inhibit tenocyte proliferation + degrade collagen via mitochondrial dysfunction
- Cardiac: block cardiac HERG (IKr) K⁺ channels → QTc prolongation → risk of torsades de pointes
- CNS: antagonize GABA-A receptors → lowered seizure threshold; may also cause peripheral neuropathy via mitochondrial toxicity
04
Diagnostics
- Diagnosis is clinical — establish temporal relationship to fluoroquinolone initiation
- ECG: QTc >500 ms is threshold for concern; obtain baseline before starting moxifloxacin/levofloxacin
- Check electrolytes (K⁺, Mg²⁺) before and during therapy in high-risk patients
- MRI Achilles: confirms tendon tear if clinical exam is uncertain
- Peripheral neuropathy: EMG/nerve conduction if prolonged symptoms; no specific lab marker
05
Management
- Discontinue fluoroquinolone immediately upon any serious adverse effect
- Tendinopathy/rupture: rest, non-weight-bearing; orthopedic referral for complete rupture
- Torsades de pointes: IV magnesium sulfate, correct electrolytes, stop drug
- Seizures: benzodiazepines acutely; avoid class in patients with epilepsy or CNS lesions
- Absolutely contraindicated in children <18 (cartilage/growth plate damage) and pregnancy; avoid with other QT-prolonging agents
06
Clinical pivots
How to separate this script from the look-alikes that show up on exams and on the wards.
Traumatic Achilles tendon rupture
Fluoroquinolone-associated rupture occurs spontaneously or with trivial exertion; recent antibiotic use is the critical clue.
Torsades de pointes from other QT-prolonging drugs (macrolides, antipsychotics)
Medication reconciliation identifies the fluoroquinolone; moxifloxacin carries the highest QT risk within the class.
Idiopathic seizure or new epilepsy
Fluoroquinolone-induced seizure has clear temporal onset with drug initiation and no prior seizure history.
Sulfonylurea-induced hypoglycemia
Fluoroquinolone dysglycemia occurs even at therapeutic doses concurrent with sulfonylurea; gatifloxacin is the prototypical offender.
Keep reading
Full library- Fibromuscular DysplasiaNon-inflammatory, non-atherosclerotic disease of medium-sized arteries causing stenosis, aneurysm, and dissection, most often in renal and carotid arteries.
- Giant Cell ArteritisLarge-vessel granulomatous vasculitis of the aorta and its branches, classically affecting the temporal artery in patients >50.
Educational use only. This illness script is a study framework, not medical advice. Confirm decisions with current guidelines and your clinical supervisors.